False-positive findings with positron emission tomography in the staging of non-small-cell lung cancer.

B. Schneider,A. Avram,B. Shulkin,G. Kalemkerian

2005-07-01

Abstract:Address correspondence to: Gregory P. Kalemkerian, MD, C350 Med Inn Building, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0848; Telephone: 734-936-5281; Fax: 734-6478792; E-mail: kalemker@umich.edu. Each year in the United States, over 170,000 new cases of lung cancer are diagnosed, the vast majority of which are non–small-cell lung cancer (NSCLC).1 Accurate staging of this disease is vital for the determination of optimal treatment, especially when considering surgical resection for curative intent. Th e use of whole-body positron emission tomography (PET) with fl uorodeoxyglucose (FDG) for staging NSCLC has dramatically increased after an early study demonstrated 96% accuracy for the detection of metastatic disease.2 Weder and colleagues3 reported that FDG-PET improved the detection of metastatic disease in patients with NSCLC that were otherwise deemed eligible for surgical resection by conventional staging methods. Twenty percent of enrolled patients were understaged prior to FDG-PET scan and there were no false-positive extrathoracic fi ndings with FDG-PET. Th ese and other studies have clearly shown that FDG-PET can be useful in avoiding unnecessary surgical resection when metastatic disease is present but undetected by computed tomography (CT) or magnetic resonance imaging (MRI).4 Unfortunately, subsequent studies have demonstrated a signifi cant false-positive rate when FDG-PET is used to detect metastatic NSCLC. Here we describe 3 patients with NSCLC for whom potentially curative surgical resection was initially cancelled due to FDG-PET fi ndings suggestive of extrathoracic metastases. In each case, further work-up with biopsy of the FDG-avid sites did not demonstrate metastatic NSCLC and the patients received surgical therapy with intent to cure early-stage disease. We also present a review of the literature to further support the need for biopsy confi rmation of metastatic disease in patients with NSCLC and isolated FDG-avid abnormalities.